Literature DB >> 18289011

New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer.

Michael Diamantidis1, Georgios Tsapournas, Jannis Kountouras, Christos Zavos.   

Abstract

Pancreatic cancer is an exceptionally devastating and incurable disease, the treatment of which has largely been unsuccessful due to higher resistance of pancreatic tumor cells to conventional approaches including surgery, radiation and/or chemotherapy. Therefore, there is a need for development of new and effective chemotherapeutic agents which can target multiple signaling pathways to induce responsiveness of pancreatic cancer cells to death signals. Although crucial advances in our understanding of the molecular pathogenesis of the disease have been made, the exceptional aggressiveness of pancreatic cancer remains largely unexplained. Investigators have actively investigated to elucidate molecular mechanisms involved in the oncogenesis, growth, invasion and metastasis of this malignancy. Pancreatic tumor cells have developed remarkable defense mechanisms to evade apoptosis and to increase their resistance to several drugs. All the typical signs of apoptosis are the final results of a complex biochemical cascade of events, whose proper function is regulated by growth and transcriptional factors, hormones and other molecules affecting the intracellular signal transduction. Understanding these complex mechanisms has created new hopes concerning pancreatic cancer in the last years and has evoked new therapeutic approaches, many of which undergo clinical trials with promising results to date. The present review provides a comprehensive description of the molecular signaling mainly of the apoptotic pathways implicated in the pathogenesis of pancreatic cancer, an incentive on the potential pathogenetic role of Helicobacter pylori infection and an appraisal of the most recent therapeutic strategies aiming at the repair of molecular lesions and applied at a cell biochemical level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18289011     DOI: 10.2174/156652408783565586

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  7 in total

1.  Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies.

Authors:  Maria P Torres; Moorthy P Ponnusamy; Subhankar Chakraborty; Lynette M Smith; Srustidhar Das; Hwyda A Arafat; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-04-27       Impact factor: 6.261

Review 2.  Granzymes-Their Role in Colorectal Cancer.

Authors:  Sara Pączek; Marta Łukaszewicz-Zając; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2022-05-09       Impact factor: 6.208

Review 3.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

4.  Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappaB signaling pathway.

Authors:  Chenghai Li; Zhengfeng Yang; Chunyan Zhai; Wenwei Qiu; Dali Li; Zhengfang Yi; Lei Wang; Jie Tang; Min Qian; Jian Luo; Mingyao Liu
Journal:  Mol Cancer       Date:  2010-04-06       Impact factor: 27.401

5.  Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy.

Authors:  Ashiq Masood; Asfar S Azmi; Ramzi M Mohammad
Journal:  Cancers (Basel)       Date:  2011-06-01       Impact factor: 6.639

6.  Knockdown of snail sensitizes pancreatic cancer cells to chemotherapeutic agents and irradiation.

Authors:  Kejun Zhang; Xuelong Jiao; Xiaoyi Liu; Bingyuan Zhang; Jigang Wang; Quan Wang; Yan Tao; Dianliang Zhang
Journal:  Int J Mol Sci       Date:  2010-11-26       Impact factor: 5.923

Review 7.  Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models.

Authors:  Patrick L Garcia; Aubrey L Miller; Karina J Yoon
Journal:  Cancers (Basel)       Date:  2020-05-22       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.